Develop the first Canadian Alcohol-related Liver Disease pathway in primary care

Background

During the COVID-19 pandemic, one in four adult Canadians has been involved in high-risk alcohol consumption (heavy drinking). At least one third of patients with high-risk alcohol consumption will have liver damage. The prevalence of advanced liver scarring (fibriosis) or end stage liver disease (cirrhosis) among these individuals is 7%.

There is no clinical care pathway in primary care to identify patients with high-risk alcoholic consumption and risk stratify them based on developing liver disease.

We propose to develop the first Canadian alcohol related liver disease pathway in primary care in Calgary. We have invited stakeholders including primary physicians, specialists in liver disease and addiction, policy makers to our committee to plan and develop this clinical care pathway. The aim of this pathway is to provide harm reduction for patients with high risk alcohol consumption and identify patients with liver fibrosis and provide timely care for them. We would like to invite patients with alcohol related liver disease or history of alcohol dependence to collaborate in our efforts and join as a main partner on our committee.

We will seek input from ideally two patient partners for:  1) the co-development of the alcohol related liver disease pathway, 2) the identification of patient engagement related barriers and facilitators for the proposed pathway, and 3) to provide insights, input and feedback in a group discussion on how to improve patient outcomes of the clinical care pathway.

Roles and Responsibilities

Patient partners will be expected to join in approximately 4-5 meetings of the pathway steering committee.

Patient partners will be expected to review the materials and drafts of the proposed pathway before the meetings and provide written and verbal feedback. Furthermore, the patient partners should be actively involved in the discussions and express any concerns or recommendations to the steering committee.

Time Commitment

This project is anticipated to start June-July 2022 and take 5 to 6 months.

It is expected there will be 4 to 5 meetings and each meeting will require about 10 hours of preparation and 2 hours for attendance.

Compensation/Reimbursement

Compensation will be offered for time and essential contribution as per AbSPORU guidelines ($25/hour).

Reimbursement will be provided for all direct, out-of-pocket expenses associated with partnering on this project including parking, etc.

This project is funded by the Canadian Institutes of Health Research.


For more information or to apply please connect with:
Abdel-Aziz Shaheen
az.shaheen@ucalgary.ca
403.592.5034
Mark Swain
swain@ucalgary.ca
403.592.5089

Subscribe to stay connected with our research and get the latest news from AbSPORU

© 2022 AbSPORU